Frederick Miesowicz, PhD

Extensive Experience in Development, Manufacturing and Automation of Cellular and RNA Therapeutics

Career Highlights

  • Consultant for North American and European cell therapy companies in process development, automation, GMP manufacturing, facility design and delivery logistics

  • Chief Operating Officer and Vice President of Manufacturing for 13 years at Argos Therapeutics. Argos developed an immunotherapy using autologous dendritic cells and tumor RNA to target antigens specific to their cancer or infectious disease

  • Directed the development and manufacturing from preclinical development to a Phase 3 clinical study in kidney cancer

  • Led development of automated devices for cellular and RNA manufacturing

  • Led technology transfer to corporate partners in Japan, Korea, China and Europe

  • FDA, EMA and Health Canada IND regulatory experience from Phase 1 to Phase 3 clinical studies for manufacturing, automation and facilities

  • Vice President of Operations for Gamida Cell Ltd. directing the process development, GMP manufacturing and Phase 2 clinical study for Gamida’s stem cell therapy

  • Senior Vice President  and General Manager of Hydridon Inc. for GMP manufacturing and commercial sale of DNA and RNA oligonucleotides used for antisense therapeutics and research

  • Vice President and General Manager of Cellcor managing their autologous
    T cell therapy to Phase 3 clinical studies in cancer

Education

  • BS, Chemistry: Siena College

  • PhD, Chemistry: Harvard University

Connect With Us

Cell One Partners

200 Central Park South

Suite 12Q

New York City, NY 10019

E: info@cellonepartners.com

© 2020 Cell One Partners